ArticleMolecular biology reports2025
Transcriptomic insights into ferroptosis and potential therapeutic targets in central Post-Stroke pain following thalamic hemorrhage.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCentral post-stroke pain (CPSP), affecting nearly one-third of stroke survivors with thalamic lesions, is increasingly linked to ferroptosis due to its established role in neuroinflammatory and neurodegenerative pathologies. This study investigates the molecular mechanisms underlying CPSP induced by thalamic hemorrhage, with a focus on the role of ferroptosis.
methodsUtilizing single-nucleus RNA sequencing and bulk RNA sequencing data from a mouse model of thalamic hemorrhage, we conducted a comprehensive analysis to identify key genes associated with CPSP and ferroptosis. We employed various bioinformatics tools, including gene set enrichment analysis (GSEA), genome-wide association study (GWAS), and Connectivity Map (CMAP) for drug prediction. To validate the key genes and ferroptosis markers identified through bioinformatic prioritization, a CPSP mouse model was established via thalamic collagenase IV injection and assessed using pain behavioral tests, RT-qPCR, and ELISA.
resultsIntegrated bioinformatics and experimental analyses identified astrocytic Gja1 as the key contributor to CPSP pathogenesis, showing significant positive correlations with pain severity scores, ferroptosis and immune infiltration levels in thalamic tissues. GWAS analysis confirmed the pathogenic regions of these genes. Additionally, we identified potential therapeutic drugs for CPSP through CMAP analysis.
conclusionOur study suggests that astrocytic Gja1 may represent a potential therapeutic target for CPSP, and implicates ferroptosis as a contributing mechanism. These findings provide a preliminary experimental basis for further investigation into targeted interventions and future therapeutic development.
Indexed as
Identifiers
41240194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.